212 related articles for article (PubMed ID: 33249427)
1. FRMD6 has tumor suppressor functions in prostate cancer.
Haldrup J; Strand SH; Cieza-Borrella C; Jakobsson ME; Riedel M; Norgaard M; Hedensted S; Dagnaes-Hansen F; Ulhoi BP; Eeles R; Borre M; Olsen JV; Thomsen M; Kote-Jarai Z; Sorensen KD
Oncogene; 2021 Jan; 40(4):763-776. PubMed ID: 33249427
[TBL] [Abstract][Full Text] [Related]
2. FRMD6 inhibits human glioblastoma growth and progression by negatively regulating activity of receptor tyrosine kinases.
Xu Y; Wang K; Yu Q
Oncotarget; 2016 Oct; 7(43):70080-70091. PubMed ID: 27661120
[TBL] [Abstract][Full Text] [Related]
3. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
Blando J; Portis M; Benavides F; Alexander A; Mills G; Dave B; Conti CJ; Kim J; Walker CL
Am J Pathol; 2009 May; 174(5):1869-79. PubMed ID: 19395652
[TBL] [Abstract][Full Text] [Related]
4. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
[TBL] [Abstract][Full Text] [Related]
5. Elevated expression of Par3 promotes prostate cancer metastasis by forming a Par3/aPKC/KIBRA complex and inactivating the hippo pathway.
Zhou PJ; Xue W; Peng J; Wang Y; Wei L; Yang Z; Zhu HH; Fang YX; Gao WQ
J Exp Clin Cancer Res; 2017 Oct; 36(1):139. PubMed ID: 29017577
[TBL] [Abstract][Full Text] [Related]
6. The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.
Luchman HA; Benediktsson H; Villemaire ML; Peterson AC; Jirik FR
PLoS One; 2008; 3(12):e3940. PubMed ID: 19081794
[TBL] [Abstract][Full Text] [Related]
7. FERM domain-containing protein 6 exerts a tumor-inhibiting role in thyroid cancer by antagonizing oncogenic YAP1.
Wang W; Zhao C; Quan F; Zhang P; Shao Y; Liu L
Biofactors; 2022 Mar; 48(2):428-441. PubMed ID: 34669997
[TBL] [Abstract][Full Text] [Related]
8. FERM domain-containing protein 6 identifies a subpopulation of varicose nerve fibers in different vertebrate species.
Beck J; Kressel M
Cell Tissue Res; 2020 Jul; 381(1):13-24. PubMed ID: 32200438
[TBL] [Abstract][Full Text] [Related]
9. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.
Ma X; Ziel-van der Made AC; Autar B; van der Korput HA; Vermeij M; van Duijn P; Cleutjens KB; de Krijger R; Krimpenfort P; Berns A; van der Kwast TH; Trapman J
Cancer Res; 2005 Jul; 65(13):5730-9. PubMed ID: 15994948
[TBL] [Abstract][Full Text] [Related]
10. CBP loss cooperates with PTEN haploinsufficiency to drive prostate cancer: implications for epigenetic therapy.
Ding L; Chen S; Liu P; Pan Y; Zhong J; Regan KM; Wang L; Yu C; Rizzardi A; Cheng L; Zhang J; Schmechel SC; Cheville JC; Van Deursen J; Tindall DJ; Huang H
Cancer Res; 2014 Apr; 74(7):2050-61. PubMed ID: 24491799
[TBL] [Abstract][Full Text] [Related]
11. The tumor suppressive effect of long non-coding RNA FRMD6-AS2 in uteri corpus endometrial carcinoma.
Wang J; Li Z; Wang X; Ding Y; Li N
Life Sci; 2020 Feb; 243():117254. PubMed ID: 31917993
[TBL] [Abstract][Full Text] [Related]
12. A novel highly potent trivalent TGF-β receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands.
Qin T; Barron L; Xia L; Huang H; Villarreal MM; Zwaagstra J; Collins C; Yang J; Zwieb C; Kodali R; Hinck CS; Kim SK; Reddick RL; Shu C; O'Connor-McCourt MD; Hinck AP; Sun LZ
Oncotarget; 2016 Dec; 7(52):86087-86102. PubMed ID: 27863384
[TBL] [Abstract][Full Text] [Related]
13. High-tissue FRMD6 expression predicts better outcomes among colorectal cancer patients.
von Koskull A; Hagström J; Haglund C; Kaprio T; Böckelman C
Biomarkers; 2024 May; 29(3):127-133. PubMed ID: 38385211
[TBL] [Abstract][Full Text] [Related]
14. CircRNA VPRBP inhibits tumorigenicity of cervical cancer via miR-93-5p/FRMD6 axis.
Shen L; Dang J; Liu S; Xian B; Deng Y; Qu D
Reprod Sci; 2022 Aug; 29(8):2251-2264. PubMed ID: 35501594
[TBL] [Abstract][Full Text] [Related]
15. Sprouty genes function in suppression of prostate tumorigenesis.
Schutzman JL; Martin GR
Proc Natl Acad Sci U S A; 2012 Dec; 109(49):20023-8. PubMed ID: 23150596
[TBL] [Abstract][Full Text] [Related]
16. Human homolog of Drosophila expanded, hEx, functions as a putative tumor suppressor in human cancer cell lines independently of the Hippo pathway.
Visser-Grieve S; Hao Y; Yang X
Oncogene; 2012 Mar; 31(9):1189-95. PubMed ID: 21785462
[TBL] [Abstract][Full Text] [Related]
17. MMAC/PTEN tumor suppressor gene regulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer.
Koul D; Shen R; Garyali A; Ke LD; Liu TJ; Yung WK
Int J Oncol; 2002 Sep; 21(3):469-75. PubMed ID: 12168088
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
[TBL] [Abstract][Full Text] [Related]
19. Willin/FRMD6 expression activates the Hippo signaling pathway kinases in mammals and antagonizes oncogenic YAP.
Angus L; Moleirinho S; Herron L; Sinha A; Zhang X; Niestrata M; Dholakia K; Prystowsky MB; Harvey KF; Reynolds PA; Gunn-Moore FJ
Oncogene; 2012 Jan; 31(2):238-50. PubMed ID: 21666719
[TBL] [Abstract][Full Text] [Related]
20. MPDZ as a novel epigenetic silenced tumor suppressor inhibits growth and progression of lung cancer through the Hippo-YAP pathway.
Liu W; Huang Y; Wang D; Han F; Chen H; Chen J; Jiang X; Cao J; Liu J
Oncogene; 2021 Jul; 40(26):4468-4485. PubMed ID: 34108620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
